SUMMARY The clinical profile of 78 patients with hypertrophic cardiomyopathy who died suddenly (or experienced cardiac arrest and survived) was analyzed. At the time of cardiac catastrophe, 71% of the patients were younger than 30 years of age, 54% were without functional limitation and 61% were performing sedentary or minimal physical activity. Nineteen of the 78 patients (24%) were taking propranolol in apparently adequate dosages, indicating that this drug does not provide absolute protection against sudden death.
PREMATURE SUDDEN DEATH is not uncommon in patients with hypertrophic cardiomyopathy.1-10 Groups of patients with hypertrophic cardiomyopathy who died suddenly have been described,"'9 but a detailed clinical and morphologic analysis of a large series of such patients is not available. It is not known whether certain clinical measurements can predict which patients with hypertrophic cardiomyopathy are at increased risk of sudden death. Thus, the present clinical profile of 78 patients with hypertrophic cardiomyopathy who died suddenly was assembled and is the subject of this report.
Patients
Autopsy records of the Pathology Branch and the patient records of the Cardiology Branch, 1960-1980, were reviewed. Sixty-six nonoperated patients with hypertrophic cardiomyopathy who died suddenly and unexpectedly were identified. Sudden death was defined as instantaneous collapse with subsequent death or documentation of ventricular fibrillation within minutes. Five of the 66 patients had survived a previous cardiac arrest with documented ventricular fibrillation 3 weeks to 26 months (median 20 months) before death.
Twelve other patients who experienced a cardiac arrest (with documented ventricular fibrillation), but who were successfully resuscitated and have survived to date were included in the study group and were considered to represent sudden deaths. These 12 patients have survived for 7 months to 15 years (mean 3.8 years) after their arrest, although one has had two subsequent occurrences of ventricular fibrillation; 10 of these 12 patients have also undergone ventricular septal myotomy-myectomy since the cardiac arrest.'" Of the 78 study patients, 29 had been evaluated at the National Heart, Lung, and Blood Institute before their death or cardiac arrest; the other 49 were either evaluated at institutions other than the National Heart, Lung, and Blood Institute or were never evaluated clinically. Fifteen patients had been chronically conditioned competitive athletes; seven of these 15 were initially identified because they were athletes who had died suddenly and were found to have hypertrophic cardiomyopathy only after examination of the heart at necropsy. '2 The diagnosis of hypertrophic cardiomyopathy was based on the presence of a hypertrophied, nondilated left ventricle in the absence of another cardiac or systemic disease capable of producing left ventricular hypertrophy.1' The presence of a hypertrophied, nondilated left ventricle was documented at necropsy in 45 patients, by echocardiography in 17 patients, by echocardiography and at necropsy in eight patients, and by left ventricular angiography in eight patients. Three patients in the study group had associated systemic hypertension, but are included because they demonstrated clinical or hemodynamic features consistent with hypertrophic cardiomyopathy'4 or because the extent of left ventricular hypertrophy clearly exceeded that which would have been expected to result from hypertension alone.', 16 Sixteen other patients with hypertrophic cardiomyopathy who died suddenly were excluded from the present study group: Five had associated, hemodynamically significant coronary artery disease documented at necropsy (i.e., atherosclerotic luminal narrowing greater than 75% of the cross-sectional area of at least one major extramural coronary artery). In six, death was clearly related to a cerebrovascular accident or other embolic phenomena, including one with a pulmonary embolus. In five, the presence of coronary heart disease could not be definitively excluded; each of these patients was older than 40 definitively exclude coronary heart disease. However, based on patient age and clinical history, we believe that it is highly unlikely that any of these 15 patients with hypertrophic cardiomyopathy had associated hemodynamically significant coronary arterial narrowing, and therefore they have been included in the study group. Seven of the 15 patients were younger than 18 years of age; five others (three men and two women) were 21-37 years old, and had never experienced chest pain. The other three (two men and one woman) had experienced episodes of chest pain but were 29, 38 and 37 years of age.
Methods

Echocardiography
The echocardiographic technique used in this study has been described. 17 Certain clinical, hemodynamic and morphologic findings in the study patients with sudden cardiac death (or cardiac arrest) were compared with a control group of surviving patients with hypertrophic cardiomyopathy. The control patients represented a consecutive series evaluated at the National Heart, Lung, and Blood Institute from February 1979 to April 1981, in whom a technically satisfactory one-or twodimensional echocardiogram identified or confirmed the diagnosis of hypertrophic cardiomyopathy.
The presence and frequency of cardiac symptoms in 76 study patients who had died suddenly (exclusive of two infants) were compared with those in 76 surviving control patients with hypertrophic cardiomyopathy, matched for age and sex. Of the 76 surviving controls, 22 had no functional limitation, 27 had mild symptoms (New York Heart Association functional class II) and 27 had substantial functional limitation (class III). Fifty-four of the 76 controls had been taking propranolol for at least 1 year, within 5 years of the time of this study; 43 of these 54 were taking a daily dosage of propranolol that was considered clinically appropriate (120 mg/day or more in adults or 2 mg/kg/day or more in children). In addition, nine patients were taking quinidine, two Pronestyl, 17 verapamil, and seven digitalis.
Left ventricular wall thicknesses in the 62 patients who died suddenly were compared with those in the first 62 patients of the control group who could be matched for age and sex. Similarly, electrocardiographic patterns in 53 patients and hemodynamic data (left ventricular outflow gradient under basal conditions and left ventricular end-diastolic pressure) in 46 patients who died suddenly were compared with ageand sex-matched surviving control patients. Thirty-three of the 71 patients (46%) had functional limitation, including 22 who were considered to be in New York Heart Association functional class II and 11 who had substantial limitation and were in class III (fig. 2) ; three of these latter 11 patients had had overt clinical manifestations of pulmonary congestion in the presence of a nondilated left ventricle and normal ejection fraction. Eight of the 33 patients with functional limitation had also had supraventricular tachycardia, including five with atrial fibrillation.
The symptoms manifested by the study patients are summarized in table 1. No symptom was significantly more common among patients who died suddenly (or experienced cardiac arrest) than in surviving controls.
Circumstances of Death
Activity at the time of sudden death or cardiac arrest was assessed in 75 patients ( fig. 3) . Excluded from this analysis were one patient in whom the precise circumstances of death could not be determined and the two patients who died in infancy.
In 58 of the 63 patients who died suddenly (exclusive of the 12 patients who survived cardiac arrest), death was virtually instantaneous. Five other patients lived for 1 hour to 6 weeks after resuscitative measures were instituted. After the initial collapse, two of these five patients had hypotension, low cardiac output and pulmonary edema and died within 24 hours; two others had recurrent ventricular tachycardia followed by a terminal arrest; and one lived for 6 weeks in coma with evidence of cerebral anoxia before dying.
At the time of the cardiac catastrophe, 46 of 75 patients (61%) were engaged in sedentary activities (e.g., lying, sitting or standing, usually in the home but while in the hospital in three patients), or participating in activities that required mild exertion (e.g., walking, shopping, throwing or performing mild calisthenics); four of these 46 patients were known to be asleep. The other 29 patients were performing moderate-tosevere exertion (e.g., running, jogging, hiking, lifting, riding a horse or diving) at the time of death, including Twenty-nine of the 78 patients had been taking propranolol in the period just before death. Nineteen of the 29 patients were reliably taking a daily dose that was considered clinically appropriate (120 mg/day or more in adults or 2 mg/kg/day or more in children) and the other 10 patients were taking less-than-adepatients with hypertrophic cardiomyopathy who have survived (mean 23.6 0.8 mm) (fig. 4) .
Posterior left ventricular free wall thicknesses (mean 14.5 0.6 mm, range 7-26 mm) were significantly greater than in controls (mean 11.8 ± 0.4 mm) (p < 0.001). Ventricular septal-to-posterior free wall thickness ratios ranged from 1.0 to 3.5 (mean 1.8 0.1); in 58 of the 62 patients (94%), the septal-free wall ratio was 1.3 or greater and therefore met our criteria for asymmetric septal hypertrophy;17 septal-free wall ratios in the controls (2.0 ± 0.1) were significantly greater (p < 0.01) than those in the patients with sudden death or cardiac arrest. The differences between control patients and patients who died suddenly with regard to posterior free wall thickness and septal-free wall ratio are probably due primarily to discrepancies inherent in comparing ventricular wall thickness measurements made at necropsy and those obtained by echocardiography during diastole.25
Hemodynamic Findings
The magnitude of the left ventricular outflow gradient was measured at cardiac catheterization in 46 patients and was estimated from the M-mode echocar- quate dosages. Two of the patients taking appropriate dosages of propranolol also received either quinidine (1200 mg/day) or Norpace (400 mg/day). Nine patients were receiving digitalis, including three'with clinical evidence of elevated pulmonary venous pressure and two with atrial fibrillation. No cardiac medication regimen was characteristic of the 12 study patients who experienced ventricular fibrillation but were successfully resuscitated. Five of the 12 patients were taking no cardioactive medications before cardiac arrest. Of the remaining seven patients, five were taking propranolol (one in lessthan-adequate dosages), one was taking a combination of propranolol and Norpace and one was taking digitalis.
Discussion
This study describes the clinical profile of patients with hypertrophic cardiomyopathy who experienced premature sudden death or cardiac arrest. Most of these patients were young, had experienced no or mild cardiac symptoms before death and were usually participating in sedentary or mild'activity at the time of death.
The data show a particular predilection of sudden death for patients younger than 30 years of age and suggest that patients older than 40 years may be at low risk for sudden death. However, certain factors related to the selection of our patients could have influenced these data. For example, older patients who die suddenly outside the hospital are commonly assumed to have had coronary heart disease; often, a necropsy examination is not performed, and hence, the diagnosis of hypertrophic cardiomyopathy is unlikely to be made. In addition, older patients with hypertrophic cardiomyopathy who die suddenly often have associated coronary heart disease,26 making it difficult to be certain which of the cardiac diseases was primarily responsible for death. In fact, our data suggest that the combination of hypertrophic cardiomyopathy and coronary heart disease may be particularly lethal; five of the 16 patients (30%) we evaluated with hypertrophic cardiomyopathy older than age 40 years who died suddenly had associated significant coronary arterial narrowing from atherosclerosis.
The fact that death usually occurred during sedentary or mild activity suggests that severe exertion may not per se be a substantial risk factor for sudden death in patients with hypertrophic cardiomyopathy. Nevertheless, since the proportion of the day during which most persons perform moderate-to-severe exertion is relatively small, the fact that about 40% of our patients died during or just after vigorous activity is impressive. Therefore, we continue to recommend that patients with hypertrophic cardiomyopathy not engage in competitive athletics or particularly strenuous physical exertion.
However, the patient with hypertrophic cardiomyopathy who died suddenly was not identified by the clinical, hemodynamic or morphologic measurements analyzed in this study, i.e., occurrence of a particular cardiac symptom, magnitude of left ventricular outflow tract obstruction under basal conditions or left ventricular end-diastolic pressure, electrocardiographic pattern or prevalence of an abnormal ECG, or degree of ventricular septal thickening. In particular, we found no significant increase in the incidence of syncope in patients with sudden death (or cardiac arrest) compared with surviving controls with hypertrophic cardiomyopathy. This finding is different from that of McKenna et al.,'0 who reported that syncope was more common among patients' with hypertrophic cardiomyopathy who died suddenly. The present data also confirm our impression that the risk of sudden death in patients with hypertrophic cardiomyopathy is not related to severity of left ventricular outflow obstruction.5 ' 7, 8 Ventricular septal thickness also did not differ substantially between patients who died suddenly and the surviving controls. Therefore, absolute ventricular septal thickness cannot be used to predict sudden death in a population of patients with hypertrophic cardiomyopathy. However, in seven of our 14 patients who had a relatively thin ventricular septum (less than 20 mm), other factors were present that could have contributed to the occurrence of a premature cardiac catastrophe: a family history of "malignant" hypertrophic cardiomyopathy7 or a competitive athletic lifestyle.
While the variables investigated in this study were not reliable in identifying that subgroup of patients with hypertrophic cardiomyopathy who are at increased risk for sudden death, two other clinical variables may be of more value. First, a familial predilection for sudden premature death may constitute a risk factor in certain families with unusually virulent expressions of hypertrophic cardiomyopathy.7 Therefore, the occurrence of premature (younger than 50 years of age) sudden death in more than one firstdegree relative of a person with known hypertrophic cardiomyopathy probably places that patient at an increased risk of sudden death. Second, preliminary data suggest that 24-hour ambulatory electrocardiographic monitoring may be useful in identifying certain patients with hypertrophic cardiomyopathy who are at increased risk for sudden death. Two prospective investigations27' 28 of patients with hypertrophic cardiomyopathy, studied by 24-or 48-hour ambulatory ECGs, have shown a significant relationship between the presence of asymptomatic ventricular tachycardia on the ambulatory ECG and the subsequent occurrence of sudden cardiac death. In our study,28 sudden cardiac catastrophe was significantly more common in patients with ventricular tachycardia on 24-hour ECG (four of 17, 25%) than in patients without ventricular'tachycardia (two of 66, 3%) (p < 0.02). However, the fact that 13 of the 17 patients with ventricular tachycardia did not experience a catastrophic cardiac event suggests that other variables must coexist in patients with hypertrophic cardiomyopathy for ventricular instability to evolve into a terminal arrhythmia.
Patients with' hypertrophic cardiomyopathy may die suddenly even while taking usual clinical dosages of propranolol. About one-fourth of the patients in this study were receiving apparently adequate amounts of propranolol during the period just before death. Thus, although propranolol does not eliminate the possibility of sudden death, well-controlled prospective studies have not, as yet, been performed to determine definitively whether patients with hypertrophic cardiomyopathy who are at high risk for sudden death and are receiving propranolol therapy have a lower mortality than untreated patients.
In the present study, surviving patients with hypertrophic cardiomyopathy had more often taken clinically appropriate dosages of propranolol than did the patients who died suddenly (43 of 78, 55%, vs 19 of 78, 24%). However, based on these data, we are hesitant to attribute to propranolol a role in enhancing survival of our patients with hypertrophic cardiomyopathy. The present study was not designed to critically determine whether propranolol reduced mortality rate. For example, patients with hypertrophic cardiomyopathy frequently may undergo alterations in their drug regimen. For the present investigation, we considered a patient in the control group to be treated with propranolol if the drug had been taken in clinically appropriate dosages for at least 1 year in the preceding 5 years, but the period these patients had actually been taking propranolol varied considerably, as did the drug dosage.
